---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-25-000059"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T11:06:25.415847+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio and ImmuneOnco report Phase 2 NSCLC trial of IMM2510 on track; initial data expected 2H 2025

## Summary
- Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.
- Initial safety and efficacy results from the Phase 2 trial anticipated in second half of 2025.
- ORR of 23.1% observed in Phase 1 monotherapy for relapsed/refractory NSCLC (efficacy evaluable n=13).
- US Phase 1b/2 monotherapy dose optimization trial of IMM2510 expected to start before end of 2025, subject to regulatory approvals.
- Phase 3 trial of IMM2510 + chemo in first-line NSCLC anticipated to start in mid-2026 in China, pending regulatory discussions.

## SEC filing metadata
- accession: 0001789769-25-000059
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/0001789769-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976925000059/til-20250522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-25-000059
- JSON: https://secwatch.observer/filing/0001789769-25-000059.json
- Plain text: https://secwatch.observer/filing/0001789769-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.